



PATENT

Customer No. 22,852

Attorney Docket No. 09605.0002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bernat VIDAL JUAN et al.

Application No.: 10/509,280

§371 Filing date: May 5, 2005

For: **NEW-4-(PYRROLOPYRIMIDIN-6-  
YL)BENZENESULPHONAMIDE  
DERIVATIVES**

Group Art Unit: 1624

Examiner: Susanna Moore

Confirmation No.: 7655

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE**  
**STATEMENT UNDER 37 C.F.R. § 1.97(c)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicant brings to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Regarding the reference by Fenner and Motschall (Arch. Pharma, 331(2):153-161 (1978)), an English-language abstract of this reference can be found on the title page of the document.

12/21/2007 SZEWDIE1 00000067 10509280

01 FC:1006

180.00 OP

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

By:   
Carlos M. Téllez  
Reg. No. 48,638

Dated: December 20, 2007